

I fw
PATENT

Case Docket No. ABGENIX.073A

Date: September 30, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Babcook, et al.
Appl. No. : 10/727,155
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO
TUMOR NECROSIS FACTOR
AND USES THEREOF
Examiner : Unknown
Group Art Unit : 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 30, 2004

(Date)


Marc C. Baumgartner, Reg. No. 53,976


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with twenty-nine (29) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Babcook, et al.
App. No. : 10/727,155
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO TUMOR
NECROSIS FACTOR AND USES THEREOF
Examiner : Unknown
Group Art Unit : 1644

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 29 references. Copies of disclosed U.S. patents and/or publications are not included pursuant to PTO waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of other references, if listed, are enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 9/30/04

By: Marc C. Baumgartner

Marc C. Baumgartner
Registration No. 53,976
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.073AAPPLICATION NO.
10/727,155INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Babcock, et al.FILING DATE
December 2, 2003GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	5,436,154	7/95	Barbanti et al.			
	2	6,090,382	7/00	Salfeld et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	3	Feldman, M. <u>Development of Anti-TNF Therapy for Rheumatoid Arthritis</u> <i>Nature Publishing Group</i> , 2(5):364-371 (2002).
	4	Michie, et al. <u>Tumour Necrosis Factor and Bacterial Sepsis</u> <i>British Journal Surgery</i> 76:670-671 (1989)
	5	Liang, et al. <u>Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin</u> <i>Biochemical and Biophysical Research Communications</i> 137(2):847-854 (1986)
	6	Meager, et al. <u>Preparation and Characterizaion of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)</u> <i>Hybridoma</i> 6(3):305-311 (1987)
	7	Fendly, et al. <u>Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor</u> <i>Hybridoma</i> 6(4):359-370 (1987)
	8	Hirai, et al. <u>Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor</u> <i>Journal of Immunological Methods</i> 96:57-62 (1987)
	9	Möeller, et al. <u>Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitor and In Vivo Appliation</u> <i>Cytokine</i> 2(3):162-169 (1990)
	10	Bringman, et al. <u>Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta Application for Affinity Purification, Immunoassays, and as Structural Probes</u> <i>Hybridoma</i> 6(5):489-507 (1987)
	11	Beutler, et al. <u>Passive Immuniation Against Cachectin/Tumor Necrosis Factor Protects Mice From Lethal Effect of Endotoxin</u> <i>Science</i> 30:869-871 (1985)

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.073AAPPLICATION NO.
10/727,155INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Babcock, et al.FILING DATE
December 2, 2003GROUP
1644

(SEVERAL SHEETS IF NECESSARY)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
12	Tracey, et al. <u>Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia</u> <i>Nature</i> 330:662-664 (1987)
13	Mathison, et al. <u>Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-Induced Injury in Rabbits</u> <i>Journal of Clinical Investigation</i> 81:1925-1937 (1988)
14	Shimamoto, et al. <u>Monoclonal Antibodies Against Human Recombinant Tumor Necrosis Factor: Prevention of Endotoxic Shock</u> <i>Immunology Letters</i> 17:311-318 (1988)
15	Opal et al. <u>Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats From Lethal Infection with Pseudomonas Aeruginosa</u> <i>The Journal of Infectious Diseases</i> 161:1148-1152 (1990)
16	Silva, et al. <u>Monoclonal Antibody to Endotoxin Core Protects Mice from Escherichia Coli Sepsis by a Mechanism Independent of Tumor Necrosis Factor and Interleukin-6</u> <i>The Journal of Infectious Diseases</i> 162:454-459 (1990)
17	Hinshaw, et al. <u>Survival of Primates in LD100 Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNFα)</u> <i>Circulatory Shock</i> 30:279-292 (1990)
18	Kumar, et al. <u>Universal T Helper Cell Determinants Enhance Immunogenicity of a Plasmodium Falciparum Merozoite Surface Antigen Peptide</u> <i>The Journal of Immunology</i> 148(5):1499-1505 (1992)
19	Babcock, et al. <u>A Novel Strategy for Generating Monoclonal Antibodies From single, Isolated Lymphocytes Producing Antibodies of Defined Specificities</u> <i>Proceedings of the National Academy of Sciences</i> 93:7843-7848 (1996)
20	Jones, et al. <u>Crystal Structure of TNF</u> <i>Tumor Necrosis Factors: Structure, Function, and Mechanism of Action</i> 5:93-127 (1992)
21	Lehmann, et al. <u>Lethal Toxicity of Lipopolysaccharide and Tumor Necrosis Factor in Normal and D-Galactosamine-Treated Mice</u> <i>Journal of Experimental Medicine</i> 165:657-663 (1987)
22	Leist, et al. <u>Tumor Necrosis Factor-Induced Hepatocyte Apoptosis Precedes Liver Failure in Experimental Murine Shock Models</u> <i>American Journal of Pathology</i> 146(5):1220-1234 (1995)
23	Nowak, et al. <u>LPS-Induced Liver Injury in D-Galactosamine-Sensitized Mice Required Secreted TNF-α and the TNF-p55 Receptor</u> <i>American Journal of Physiological Society</i> 278:R1202-R1209 (2000)
24	Benigni, et al. <u>TNF Receptor p55 Plays a Major Role in Centrally Mediated Increases of Serum IL-6 and Corticosterone After Intracerebroventricular Injection of TNF1</u> <i>The American Association of Immunologists</i> 0022-1767:5563-5568 (1996)
25	Chothia, et al. <u>Canonical Structures for the Hypervariable Regions of Immunoglobulins</u> <i>Journal of Molecular Biology</i> 96:901-917 (1987)
26	Chothia, et al. <u>Conformations of Immunoglobulin Hypervariable Regions</u> <i>Nature Publishing Group</i> 342:877-883 (1989)
27	Martin, et al. <u>Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies</u> <i>Journal Molecular Biology</i> 263:800-815 (1996)
28	Ostade, et al. <u>Human TNF Mutants With Selective Activity on the p55 Receptor</u> <i>Nature</i> 361:266-269 (1993)
29	Ostade, et al. <u>Localization of the Active Site of Human Tumor Necrosis Factor (hTNF) by Mutational Analysis</u> <i>The EMBO Journal</i> 10(4):827-836 (1991)

S:\DOCS\WCB\WCB-2978.DOC
082704

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	